Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
Pluri Inc. develops cell-based technologies built around its proprietary 3D cell expansion platform. Company news commonly covers mass-scale cell expansion, biofarming, regenerative medicine applications, immune-cell manufacturing intellectual property, and the use of PluriCDMO™ for contract development and manufacturing programs involving cell-derived therapeutics, biologics, and placenta-derived biomaterials.
Recurring updates also address Pluri’s venture and subsidiary activity across foodtech, agtech, and health and aesthetics, including Coffeesai, Ever After Foods, Kokomodo, and Cellav. Additional news themes include commercial collaborations, patent grants, board and governance changes, private placements, and other capital actions tied to Pluri’s platform, subsidiaries, and public-company structure.
Pluri (Nasdaq, TASE: PLUR) announced a private placement on March 26, 2026 in which an entity beneficially owned by Chairman Alejandro Weinstein will invest an additional $2.5 million at a 30% premium to the March 24, 2026 market price.
The offering consists of 625,000 common shares and warrants to purchase up to 625,000 common shares at a combined purchase price of $4.00 per share/warrant; warrants are exercisable immediately at $4.25 and expire 18 months after closing. Proceeds are for general working capital and corporate purposes.
Pluri (Nasdaq: PLUR) announced that China's CNIPA granted a patent (Cn 119301238 b) for its proprietary 3D immune cell expansion and activation technology, extending an existing global patent family that includes the U.S., Japan, Korea, Australia and Israel.
The patent covers large-scale production of diverse immune cell types, supports automated, closed-loop manufacturing that targets billion-cell batches, and is positioned to enable international licensing and partnerships in China’s growing cell therapy market.
Pluri (NASDAQ, TASE: PLUR) announced completion of the first phase of its PluriCDMO program with Resbiomed on Jan 22, 2026. The initial phase covered process development and feasibility for scalable production of placenta-derived, collagen-rich biomaterials. Next phase will target process definition, reproducibility and manufacturing readiness, subject to mutually agreed scope and timelines. Pluri applied proprietary placenta-based processing and bioprocessing expertise to establish tissue extraction and processing protocols aimed at preserving and concentrating endogenous human collagen for regenerative-medicine applications.
Pluri (Nasdaq, TASE: PLUR) and Remedy Cell announced an expanded manufacturing collaboration on Dec 22, 2025. PluriCDMO completed implementation of Remedy Cell’s proprietary process in its GMP facility, provided GMP training and qualification, executed engineering runs to confirm process robustness and scalability, and manufactured several clinical-grade batches of Remedy Cell’s lead candidate for a planned Phase 1b clinical trial.
The companies will broaden the agreement so PluriCDMO continues providing manufacturing and process-development support as Remedy Cell advances clinical and pre-commercial programs, positioning PluriCDMO as a CDMO partner for complex cell-derived and cell-free biologics.
Pluri (Nasdaq, TASE: PLUR) appointed shareholder Alejandro Weinstein as Chairman on Dec 9, 2025, while prior Chairman Zami Aberman will transition to Vice Chairman. Weinstein’s ownership is expected to rise to approximately 30%, and he brings a track record including a prior company sale to Abbott for $2.9 billion.
Pluri entered a private placement where an entity beneficially owned by Weinstein will purchase 625,000 common shares plus warrants for an additional 625,000 shares at a combined purchase price of $4, generating gross proceeds of ~$2.5 million. Warrants exercise price is $4.25, exercisable immediately until June 30, 2026. Proceeds are for general working capital.
Pluri (NASDAQ, TASE: PLUR) announced multiple industry honors on Nov 13, 2025, highlighting progress in applying its proprietary 3D cell expansion platform to agriculture and food systems.
Key recognitions include Overall BioAgriculture Company of the Year from Biotech Breakthrough Awards, AgriNext’s award for Coffeesai Ltd. for sustainable cell‑based coffee production, MassChallenge Switzerland 2025 gold for Kokomodo Ltd., and a listing on Dun’s 100 Best HighTech Companies to work for 2025. Pluri also won Israel’s 2024 Egalitarian Employment Award (Large Company) and expects a government grant of 40,000 NIS.
Pluri (NASDAQ, TASE: PLUR) launched a wholly-owned subsidiary, Cellav Health and Aesthetics, to commercialize exosome-enhanced regenerative skincare using Pluri’s proprietary 3D cell expansion platform.
Pluri announced a commercial collaboration with Miss Universe Skincare to co-develop a line of cell-based skincare products, with the first product expected to launch in the first half of 2026 and be distributed via Miss Universe Skincare’s global platform. The collaboration will be presented during pre-gala activities of the 74th Miss Universe event in Thailand. Management describes the move as part of Pluri’s strategy to enter high-growth, revenue-generating beauty markets.
Pluri (NASDAQ, TASE: PLUR) announced on November 10, 2025 a series of international strategic collaborations across Asia, Europe and the U.S. through its subsidiaries Ever After Foods, Kokomodo and Coffeesai to advance cultivated meat, cultivated cacao and cell-based coffee.
Each collaboration is anchored by a collaborator-funded minimum-viable-product (MVP) / proof-of-concept to support scale-up validation, pre-commercial trials and pilot results, with near-term milestones focused on pilot readouts and expansion of collaborator programs in priority markets.
Pluri (NASDAQ/TASE: PLUR) subsidiary Coffeesai signed a collaboration with the Instituto del Café de Chiapas on Oct 8, 2025 to advance cell-based coffee manufacturing in Chiapas, Mexico. The agreement establishes a three-phase roadmap: cell line development, pilot-scale 3D bioreactor biofarming in Chiapas, and evaluation of commercial-scale manufacturing subject to definitive agreements and approvals. The partnership aims for non-dilutive license and technology-transfer revenues, royalty-bearing models and joint ventures to access the >$250B global coffee market. Coffeesai will begin Phase 1 immediately to validate cell lines, then deploy pilot-scale operations to test scalability and process robustness.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has signed a Letter of Intent with Minaris Advanced Therapies for manufacturing NurOwn®, its adult stem cell therapy for ALS treatment. The partnership will facilitate technology transfer and clinical trial manufacturing at Minaris' Allendale, New Jersey facility in preparation for BrainStorm's planned Phase 3b clinical trial.
This U.S.-based manufacturing collaboration complements BrainStorm's recent partnership with Pluri Inc. (Nasdaq: PLUR) in Israel, establishing a robust manufacturing network for NurOwn®. The strategic relationship aims to advance the clinical development of this therapy for ALS patients through a multicenter Phase 3b trial.